Alpa Laboratories Limited has submitted revised consolidated financial results for the quarter ended March 31, 2026, to the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited to rectify an inadvertent error in its initial XBRL filing. The company corrected the discrepancy on July 23, 2026, ensuring that the Profit Before Tax (PBT) reported in the revised digital submission is fully aligned with the figures appearing in the signed PDF of the Consolidated Financial Results previously provided to the exchanges.

The revision was filed under Regulation 33(3) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates the disclosure of financial results. The company stated that the earlier XBRL filing contained errors that were subsequently identified and corrected before resubmission.

Filing Details

The revised consolidated financial results were submitted via the NEAPS platform and received acknowledgments from both stock exchanges. The key details of the submission are as follows:

The company communicated this clarification to the listing departments of both exchanges on July 24, 2026, requesting that the correction be taken on record. The notice was signed by Yashoda Patidar, Company Secretary of Alpa Laboratories Limited.

What This Means for Investors

The correction ensures data integrity for investors relying on digital filings for analysis. While the underlying financial performance metrics remain unchanged from the signed PDF report, the alignment between the XBRL and PDF versions eliminates potential confusion regarding the Profit Before Tax figure for Q4FY26. Investors should refer to the revised XBRL filing for accurate digital data points.

Alpa Laboratories has announced the cessation of Ms. Jyoti Jain as an Independent Director following the completion of her tenure. The change in the board composition was effective from the close of business hours on July 21, 2026. The company informed the stock exchanges regarding this development in accordance with regulatory requirements.

The intimation was submitted under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure details were provided in compliance with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Details of Cessation

The company provided specific particulars regarding the director's departure in an annexure to the regulatory filing. The reason cited for the change was the completion of the tenure of Ms. Jyoti Jain, who held the DIN 07554658.

The filing was signed by Yashoda Patidar, Company Secretary and Compliance Officer of Alpa Laboratories Ltd. The notification was addressed to the Listing Departments of the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited.